Innovation and The Supreme Court: Two Cases to Watch

An inside look at two cases facing the Supreme Court of the United States: <a href=""><u>Bowman v. Monsanto</u></a>&nbsp;and <a href=" Pathology v. Myriad Genetics</u></a>.&nbsp;</p>



An inside look at two cases facing the Supreme Court of the United States: Bowman v. Monsantoand Molecular Pathology v. Myriad Genetics


This call will provide you with experts who will explain the broad reaching impacts and implications of these two very different cases, each of which present distinct questions of patent law that could affect the future of innovation in biotechnology in different ways.  In Bowman v. Monsanto, the Supreme Court will address whether patent law prevents the reproduction of patented products -like genetically engineered seeds, live vaccines, synthetic cell lines, nucleic acid preparations,  and other promising new scientific products-that, as a technological matter, can be easily reproduced at exponential rates.  In Association for Molecular Pathology v. Myriad Genetics, the Court will address, as a threshold matter of patent law, whether laboratory preparations of isolated DNA molecules that were derived from natural sources can be eligible for patenting.



  • Jim Greenwood, President & CEO, BIO
  • Hans Sauer, Deputy General Counsel, Intellectual Property, BIO
  • Gary Baise, Olsson Frank Weeda Terman Matz PC; Counsel of Record, American Soybean Association
  • Scott McBride, McAndrews, Held & Malloy; Counsel of record for the Wisconsin Alumni Research Foundation
  • Christopher Holman, University of Missouri – Kansas City School of Law



Thursday, February 14 , 2013, 11:00a.m.- 12:30 p.m.  EDT

11:00-11:45 – Part I: Bowman v. Monsanto – discussion and Q&A

11:45-12:30 – Part II: Molecular Pathology v. Myriad Genetics – discussion and Q&A



Conference Call
Dial-In #: 1-866-393-9713
Conference Code PIN: 5246534849